A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Completed · Phase 2

Conditions studied: Parkinson Disease

In brief

To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.

Key facts

Study ID

NCT00148486

Run by

Boehringer Ingelheim

People needed

261

Starts

2003-06-01

Last updated by the study team

2013-10-29

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Boehringer Ingelheim Investigational Site — Tucson, Arizona, United States
• PMDI — Fountain Valley, California, United States
• Boehringer Ingelheim Investigational Site — Fresno, California, United States
• Boehringer Ingelheim Investigational Site — Irvine, California, United States
• Boehringer Ingelheim Investigational Site — Ocenside, California, United States
• Boehringer Ingelheim Investigational Site — Oxnard, California, United States
• West Los Angeles VA Medical Center — West Los Angeles, California, United States
• Boehringer Ingelheim Investigational Site — Danbury, Connecticut, United States
• UCONN Health Center — Farmington, Connecticut, United States
• 60 Temple St — New Haven, Connecticut, United States
• Boehringer Ingelheim Investigational Site — Boca Raton, Florida, United States
• Boehringer Ingelheim Investigational Site — Bradenton, Florida, United States
• University of Florida — Gainsville, Florida, United States
• Sunrise Clinical Research — Hollywood, Florida, United States
• Department of Neurology — Miami, Florida, United States
• Miami Research Associates — Miami, Florida, United States
• Boehringer Ingelheim Investigational Site — Ocala, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Boehringer Ingelheim Investigational Site — Panama City, Florida, United States
• CNS Clinical Trials — Saint Piresburg, Florida, United States
• Movement Disorder Center — Tampa, Florida, United States
• University of Southern Florida — Tampa, Florida, United States
• Department of Neurological Sciences — Chicago, Illinois, United States
• Boehringer Ingelheim Investigational Site — Fort Wayne, Indiana, United States
• Pivotal Reaserch Centers — Peoria, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.